⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NGNE News
Neurogene, Inc. Common Stock
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
NGNE
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
businesswire.com
NGNE
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
businesswire.com
NGNE
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
NGNE
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
NGNE